EP1968559A4 - Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete - Google Patents

Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete

Info

Publication number
EP1968559A4
EP1968559A4 EP06844984.2A EP06844984A EP1968559A4 EP 1968559 A4 EP1968559 A4 EP 1968559A4 EP 06844984 A EP06844984 A EP 06844984A EP 1968559 A4 EP1968559 A4 EP 1968559A4
Authority
EP
European Patent Office
Prior art keywords
diabetes
treatment
metabolic syndrome
botanical products
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06844984.2A
Other languages
German (de)
English (en)
Other versions
EP1968559A2 (fr
Inventor
Matthew L Tripp
John G Babish
Jeff Bland
Amy Jennae Hall
Veera Konda
Linda Pacioretty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MetaProteomics LLC
Original Assignee
MetaProteomics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MetaProteomics LLC filed Critical MetaProteomics LLC
Priority to EP14000382.3A priority Critical patent/EP2737897A3/fr
Publication of EP1968559A2 publication Critical patent/EP1968559A2/fr
Publication of EP1968559A4 publication Critical patent/EP1968559A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/235—Foeniculum (fennel)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EP06844984.2A 2005-12-09 2006-12-07 Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete Withdrawn EP1968559A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14000382.3A EP2737897A3 (fr) 2005-12-09 2006-12-07 Produits botaniques anti-inflammatoires pour le traitement du syndrome métabolique et le diabète

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74890705P 2005-12-09 2005-12-09
PCT/US2006/046770 WO2007070355A2 (fr) 2005-12-09 2006-12-07 Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP14000382.3A Division EP2737897A3 (fr) 2005-12-09 2006-12-07 Produits botaniques anti-inflammatoires pour le traitement du syndrome métabolique et le diabète

Publications (2)

Publication Number Publication Date
EP1968559A2 EP1968559A2 (fr) 2008-09-17
EP1968559A4 true EP1968559A4 (fr) 2013-08-07

Family

ID=38163414

Family Applications (2)

Application Number Title Priority Date Filing Date
EP14000382.3A Withdrawn EP2737897A3 (fr) 2005-12-09 2006-12-07 Produits botaniques anti-inflammatoires pour le traitement du syndrome métabolique et le diabète
EP06844984.2A Withdrawn EP1968559A4 (fr) 2005-12-09 2006-12-07 Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP14000382.3A Withdrawn EP2737897A3 (fr) 2005-12-09 2006-12-07 Produits botaniques anti-inflammatoires pour le traitement du syndrome métabolique et le diabète

Country Status (5)

Country Link
EP (2) EP2737897A3 (fr)
JP (1) JP2009518429A (fr)
AU (1) AU2006326658A1 (fr)
CA (1) CA2632607A1 (fr)
WO (1) WO2007070355A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008115163A (ja) * 2006-10-10 2008-05-22 Kikkoman Corp アディポネクチン産生増強・促進剤
EP2291182A1 (fr) * 2008-05-13 2011-03-09 Genmedica Therapeutics SL Conjugués de salicylés utiles pour le traitement de troubles métaboliques
TWI492755B (zh) * 2009-12-30 2015-07-21 Metal Ind Res & Dev Ct 抗糖尿病及抗新陳代謝疾病之香椿超臨界萃取物、製備方法及用途
CN110200955A (zh) 2010-10-30 2019-09-06 金戴克斯治疗学有限责任公司 四氢异-α酸衍生物、组合物及方法
CN102821771B (zh) * 2010-12-28 2015-01-14 高雄医学大学 抗糖尿病及抗新陈代谢疾病的香椿超临界萃取物、制备方法及用途
AU2019317043A1 (en) 2018-08-10 2021-02-04 Suntory Holdings Limited Composition and method for suppressing increase in blood glucose level
EP4079302A4 (fr) * 2019-12-20 2023-12-20 Daicel Corporation Composition pour supprimer l'obésité

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003996A1 (fr) * 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Utilisation de saponines de triterpenoide de type dammarane
US6451355B1 (en) * 2000-07-17 2002-09-17 Howard M. Reisner Composition to treat diabetes
US6511683B1 (en) * 1999-09-30 2003-01-28 Factors R & D Technologies Ltd. Enchinacea supplement and method of manufacture
JP2005047822A (ja) * 2003-07-30 2005-02-24 Japan Research & Development Association For New Functional Foods 高血糖障害抑制剤
US20050074447A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Treatment for diabetic microvascular and macrovascular complications
CN1608644A (zh) * 2003-10-21 2005-04-27 陈钟 一种治疗糖尿病的胶囊

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4497566B2 (ja) * 1998-09-02 2010-07-07 株式会社 日本薬用食品研究所 アルドース還元酵素阻害剤並びに新規サポニン及び新規サポゲノール
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US7205151B2 (en) * 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7279185B2 (en) * 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
TW200301705A (en) * 2002-01-10 2003-07-16 Biosynergen Inc A pharmaceutical composition and function foods for prevention and treatment of diabets millitus
JPWO2003068205A1 (ja) * 2002-02-14 2005-06-02 麒麟麦酒株式会社 肥満治療剤および肥満防止または改善用食品
JP2006508182A (ja) * 2002-10-21 2006-03-09 メタプロテオミクス， エルエルシー 炎症応答と関連した病理学的状態を処置または抑制する組成物。
JPWO2004045632A1 (ja) * 2002-11-12 2006-03-16 株式会社カネカ ペルオキシソーム増殖剤応答性受容体リガンド剤
WO2004075844A2 (fr) * 2003-02-26 2004-09-10 Unigen Pharmaceuticals, Inc. Preparation destinee a prevenir et traiter des maladies et des etats pathologiques induits par les glucides
WO2004110422A1 (fr) * 2003-06-16 2004-12-23 Ranbaxy Laboratories Limited Comprimes a liberation controlee de metformine
EP1510208A1 (fr) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Compositions pharmaceutiques comprenant une combinaison de metformine et de statine
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
JP2009504657A (ja) * 2005-08-09 2009-02-05 メタプロテオミクス，エルエルシー ホップ及びアカシア産物によるプロテインキナーゼ調節

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511683B1 (en) * 1999-09-30 2003-01-28 Factors R & D Technologies Ltd. Enchinacea supplement and method of manufacture
WO2002003996A1 (fr) * 2000-07-12 2002-01-17 RAJKUMAR, Sujatha Utilisation de saponines de triterpenoide de type dammarane
US6451355B1 (en) * 2000-07-17 2002-09-17 Howard M. Reisner Composition to treat diabetes
JP2005047822A (ja) * 2003-07-30 2005-02-24 Japan Research & Development Association For New Functional Foods 高血糖障害抑制剤
US20050074447A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Treatment for diabetic microvascular and macrovascular complications
CN1608644A (zh) * 2003-10-21 2005-04-27 陈钟 一种治疗糖尿病的胶囊

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AGGARWAL BHARAT B ET AL: "Suppression of the nuclear factor-kappa B activation pathway by spice-derived phytochemicals - Reasoning for seasoning", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 1030, 1 December 2004 (2004-12-01), pages 434 - 441, XP009097664, ISSN: 0077-8923, DOI: 10.1196/ANNALS.1329.054 *
ARORA DEEPA ET AL: "Immunomodulating effects of rasayana drugs in diabetics - a clinical study.", ANCIENT SCIENCE OF LIFE OCT 2002, vol. 22, no. 2, October 2002 (2002-10-01), pages 42 - 48, XP018015455, ISSN: 0257-7941 *
DATABASE WPI Week 200519, Derwent World Patents Index; AN 2005-176026, XP002699141 *
DATABASE WPI Week 200560, Derwent World Patents Index; AN 2005-583447, XP002699140 *
HOU C C ET AL: "Bacopaside III, bacopasaponin G, and bacopasides A, B, and C from Bacopa monniera", MEDICINAL & AROMATIC PLANTS ABSTRACTS, SCIENTIFIC PUBLISHERS, SCIENTIFIC PUBLISHERS, NEW DELHI - INDIA, vol. 25, no. 4, 1 August 2003 (2003-08-01), XP018007587, ISSN: 0250-4367 *
OOMAH B DAVE ET AL: "Characteristics of raspberry (Rubus idaeus L.) seed oil", FOOD CHEMISTRY, vol. 69, no. 2, March 2000 (2000-03-01), pages 187 - 193, XP002699143, ISSN: 0308-8146 *
RANA T S ET AL: "Studies on indigenous herbal remedies for diabetes mellitus in India", BIOSIS,, 15 September 1990 (1990-09-15), XP002572903 *
SUBRAMONIAM A ET AL: "EFFECTS OF ARTEMISIA PALLENS WALL. ON BLOOD GLUCOSE LEVELS IN NORMAL AND ALLOXAN-INDUCED DIABETIC RATS", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 50, no. 1, 1 January 1996 (1996-01-01), pages 13 - 17, XP002038211, ISSN: 0378-8741, DOI: 10.1016/0378-8741(95)01329-6 *
WANG X-S ET AL: "Study on hypoglycemic polysaccharide from Centalla asiatica", CHINESE PHARMACEUTICAL JOURNAL NOVEMBER 2005 CHINESE MEDICAL ASSOCIATION CN, vol. 40, no. 22, November 2005 (2005-11-01), pages 1697 - 1700, XP009170472 *

Also Published As

Publication number Publication date
WO2007070355A3 (fr) 2008-07-03
EP1968559A2 (fr) 2008-09-17
EP2737897A2 (fr) 2014-06-04
CA2632607A1 (fr) 2007-06-21
JP2009518429A (ja) 2009-05-07
WO2007070355A2 (fr) 2007-06-21
EP2737897A3 (fr) 2014-10-01
AU2006326658A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
EP2007385A4 (fr) Composition cardiovasculaire et utilisation de ladite composition pour le traitement de la maladie d'alzheimer
EP1991218A4 (fr) Utilisation de cyclolignans dans le traitement du diabète de type 2 et comme contraceptifs
PL2118074T3 (pl) Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
IL184312A0 (en) Herbal compositions for the treatment of diabetes and/or conditions associated therewith
IL185277A0 (en) Pharmaceutical compositions containing roflumilast for the treatment of diabetes
IL173060A0 (en) Medical product expiration alerting
IL200616A0 (en) Co-crystals and pharmaceutical compositions comprising the same
PL2018184T3 (pl) Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego
EP2137175A4 (fr) Nouveau composé à base de phénanthrènequinone et composition pharmaceutique contenant ce dernier utilisé pour le traitement ou la prévention du syndrome métabolique impliquant des maladies
EP1982724A4 (fr) Agent therapeutique pour le traitement du syndrome metabolique et aliments contenant cet agent
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
EP2199295A4 (fr) Composés constitués d'un cycle de 7 chaînons et son utilisation pharmaceutique pour la prévention et le traitement du diabète et d'un syndrome métabolique
EP1968559A4 (fr) Produits botaniques anti-inflammatoires pour le traitement du syndrome metabolique et du diabete
IL208463A (en) 2-Trotocyclic-Pirol compounds combined, pharmaceutical preparations containing them and their use in the prevention or treatment of diabetes or obesity
EP2056857A4 (fr) Compositions pharmaceutiques comprenant ccl2 et leur utilisation dans le traitement d'une inflammation
EP2010164A4 (fr) Compositions contenant des s-nitrosothiols pour traiter les steatoses hepatiques, l'obesite ainsi que d'autres maladies liees au synchrome matabolique et utilisation de ces compositions
EP2170932A4 (fr) Compositions et leurs utilisations dans le traitement du syndrome de détresse respiratoire aigu (ards) et de troubles cliniques associés à celui-ci
EP2231148A4 (fr) Composition pharmaceutique utilisée dans le traitement et la prévention d'une maladie cardiaque
EP2231146A4 (fr) Composition pharmaceutique pour le traitement et la prévention du glaucome
IL211267A (en) Oxadiazole derivatives and drugs and their use in the treatment of diabetes
EP1997487A4 (fr) Produit utilise dans la prevention et le traitement de maladies cardiovasculaires, de cancers et de maladies inflammatoires chroniques
ZA200705349B (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
EP2014283A4 (fr) Agent anti-inflammatoire et agent de prévention du cancer comprenant du canolol ou un promédicament de celui-ci et produit pharmaceutique, cosmétique et alimentaire comprenant celui-ci

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080703

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1122221

Country of ref document: HK

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/01 20060101AFI20130627BHEP

Ipc: A61K 36/48 20060101ALI20130627BHEP

Ipc: A61K 36/282 20060101ALI20130627BHEP

Ipc: A61K 36/68 20060101ALI20130627BHEP

Ipc: A61K 36/185 20060101ALI20130627BHEP

Ipc: A61K 36/73 20060101ALI20130627BHEP

Ipc: A61K 36/235 20060101ALI20130627BHEP

Ipc: A61K 36/80 20060101ALI20130627BHEP

Ipc: A61K 36/31 20060101ALI20130627BHEP

Ipc: A61K 36/23 20060101ALI20130627BHEP

Ipc: A61P 5/48 20060101ALI20130627BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130705

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140204

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1122221

Country of ref document: HK